Adicet Bio Q3 net loss narrows 30% to $18.88 million

Bitget2026/11/05 21:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adicet Bio's third-quarter 2026 net loss narrowed 30% year over year to $18.88 million.
Research and development expenses fell 32% to $15.63 million, while general and administrative expenses dropped 18% to $4.17 million year over year.
Cash, cash equivalents and short-term investments totaled $100.95 million at September 30, with funding expected to last into the second half of 2027.
Prula-cel pivotal lupus nephritis study startup activities are underway, with a regulatory update and additional 12-month data expected in first-quarter 2027.
ADI-212 patient enrollment for metastatic castration-resistant prostate cancer is anticipated in first-quarter 2027 following FDA clearance of its investigational new drug application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611051610BIZWIRE_USPR_____20261105_BW996835) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Adicet Bio Q3 net loss narrows 30% to $18.88 million

You may also like

Crypto prices